Oncologist 2020 Mar 10
Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.
Related Questions
What are there most evidence-based options?
New answer by Medical Oncologist at Memorial Sloan Kettering Cancer Center (June 28, 2020)
Fibrolamellar carcinoma is histologically unique from hepatocellular carcinoma. The disease is correctly called fibrolamellar carcinoma, and not fibrolamellar hepatocellular c...